CDKN2A and glioblastoma: As is the case of METTL3 in glioblastoma, METTL14 depletion facilitates the malignant phenotype, characterized by upregulated oncogenes such as ADAM19 and reduced expression of tumor suppressors such as CDKN2A (42).